Not finding it? Sign in to also search OpenAlex live.
-
689P Predicting oncotype DX recurrence score using clinicopathological variables in HR-positive, HER2-negative breast cancer: A real-world analysis from an Italian breast unit2026 ESMO Open article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
P.J. Paganoni, M. Laganà, Matteo Rota, D. Cosentini, G. Mola, Greta Schivardi, +5 more
0citations -
Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, Influence, CTS-5)? A TEAM Pathology substudy.2023 Journal of Clinical Oncology conference-abstract Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
Ana-Alicia Beltran-Bless, Gregory R. Pond, Jane Bayani, Sarah Barker, Melanie Spears, Elizabeth Mallon, +11 more
0citations -
Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, INFLUENCE 2.0, CTS5)?2025 The Breast article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
Ana-Alicia Beltran-Bless, Gregory R. Pond, Jane Bayani, Sarah L. Barker, Melanie Spears, Elizabeth Mallon, +10 more
4citations -
Gene expression signatures in older patients with breast cancer: A systematic review2022 Critical Reviews in Oncology/Hematology review Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
Annelieke A. Lemij, Joosje C. Baltussen, Nienke A. de Glas, Judith R. Kroep, Marloes G.M. Derks, Gerrit‐Jan Liefers, +1 more
9citations -
Comparative survival analysis of multiparametric tests—when molecular tests disagree—A TEAM Pathology study2021 npj Breast Cancer article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
John M.S. Bartlett, Jane Bayani, Elizabeth N. Kornaga, Keying Xu, Gregory R. Pond, Tammy Piper, +11 more
11citations -
ADAPTcycle: Adjuvant dynamic marker-adjusted personalized therapy (ADAPT) comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2- early breast cancer (EBC).
Nadia Harbeck, Oleg Gluz, Matthias Christgen, Monika Graeser, Felix Hilpert, Katja Krauss, +11 more
18citations -
Chemotherapy and gene expression profiling in older early luminal breast cancer patients: An International Society of Geriatric Oncology systematic review2022 European Journal of Cancer review Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
Nicolò Matteo Luca Battisti, Nienke A. de Glas, Enrique Soto‐Pérez‐de‐Celis, Gabor Istvan Liposits, Michaël Bringuier, Christine Marie Walko, +8 more
13citations -
Evaluation of multiple transcriptomic gene risk signatures in male breast cancer2021 npj Breast Cancer article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
Jane Bayani, Coralie Poncet, Cheryl A. Crozier, Anouk Neven, Tammy Piper, Carrie Cunningham, +30 more
10citations -
Concordance and clinical impact of ER, PR, HER2 expression by local and central immunohistochemistry versus RT-PCR in HR+/HER2- early breast cancer (EBC): Results from the ADAPT trial.2022 Journal of Clinical Oncology conference-abstract Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies
Oleg Gluz, Matthias Christgen, Sherko Küemmel, Christine zu Eulenburg, Michael S Braun, Bahriye Aktas, +14 more
1citations -
Guiding treatment decisions in early breast cancer: A model-based comparison of the OncotypeDX and MammaPrint tests2026 The Breast article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
Frank Doornkamp, Liesbeth C. de Wreede, Elfi M. Verheul, Agnes Jager, Ewout Willem Steyerberg
0citations
13 results